So I just watched the Procactive Investor interview with MV who explained that,
"Immutep is a biotech company focused on Oncology and auto immune diseases, so two big disease areas if you like ..."
When questioned on the status of auto immune diseases he explained that there was a very nice publication about IMP761 in the journal of Immunology last year and that we will bring this forward to IND stage in 18 to 24 months ....
Wow looks like one of the big focus areas of the company is dragging its feet.
Media, page-47
-
- There are more pages in this discussion • 697 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.015(4.92%) |
Mkt cap ! $464.8M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 32.5¢ | 30.0¢ | $1.168M | 3.702M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 148547 | 32.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.5¢ | 51809 | 2 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |